PYC announced on 17th August that dosing had been completed for...

PYC announced on 17th August that dosing had been completed for Cohort #1.

My understanding is that PYC then accumulates data for the ensuing 4 weeks and submits this data for review, and if all is well, for the Safety Committee to provide approval to start clinical dosing for Cohort #2, (medium dose).

Next Thursday, 14th September, marks four weeks since that announcement on 17th August.

I believe that as we progress to Cohort #2, medium dose, we will be getting into a dosage metric that more likely carries the possibility of VP - 001 to demonstrate its potential to provide measurable eyesight improvements for patients, (over time). This comment is not meant to underscore the safety profile of VP - 001, as patient safety needs to be an absolute priority, however with Cohort #2 we are also moving into a space that may further validate our safety profile PLUS quite a bit more.